STEMGenX harnesses the power of stem cell biology, gene editing, and precision medicine to develop therapies that heal, regenerate, and restore.
Founded in 2018, STEMGenX is a clinical-stage biotechnology company focused on unlocking the therapeutic potential of stem cells and genomic medicine. Our interdisciplinary team combines expertise in molecular biology, bioengineering, and translational research to deliver transformative therapies.
Transforming breakthrough science into life-changing therapies for patients with unmet medical needs.
Proprietary stem cell differentiation and gene editing platforms enable rapid therapeutic discovery.
Partnerships with leading academic centers and pharmaceutical companies across North America and Europe.
Six focused research programs targeting regenerative medicine, neurodegeneration, and genetic disorders.
Induced pluripotent stem cell (iPSC)-derived cardiomyocytes for treating ischemic heart disease and heart failure. Our proprietary differentiation protocol achieves >95% purity.
Novel biomaterial scaffolds combined with mesenchymal stem cells to regenerate cartilage and bone tissue for orthopedic and dental applications.
CRISPR-Cas9 mediated gene correction for inherited monogenic disorders including sickle cell disease and beta-thalassemia using ex vivo hematopoietic stem cell editing.
Dopaminergic neuron transplantation derived from patient-specific iPSCs for Parkinson's disease, with integrated safety monitoring via embedded biosensors.
Engineered natural killer (NK) cells from universal donor iPSC lines for the treatment of solid tumors and hematologic malignancies.
Human organoid platforms for disease modeling, drug screening, and personalized medicine — liver, kidney, and brain organoids in development.
Key achievements that have shaped our path from discovery to clinic.
STEMGenX established by a team of stem cell biologists from Stanford and MIT. Seed funding of $15M raised from leading biotech VCs.
Proprietary iPSC differentiation platform published in Nature Biotechnology. First patent family filed covering novel differentiation protocols.
Major funding round led by Atlas Venture to advance cardiomyocyte therapy into clinical development and expand organoid platform.
IND application accepted by FDA for STEM-001 (iPSC-derived cardiomyocyte therapy). First patient dosed in Phase I/II trial at Johns Hopkins.
Published landmark results in The Lancet demonstrating successful ex vivo CRISPR editing of hematopoietic stem cells with durable engraftment.
Positive topline Phase II data for STEM-001 announced. Pipeline expanded to 12 programs. New 50,000 sq ft R&D facility opened in Boston.
World-class scientists, clinicians, and industry veterans driving innovation from bench to bedside.
Former VP at Gilead Sciences. 20+ years in biotech leadership. PhD in Molecular Biology, UCSF.
Pioneer in iPSC research. Former principal investigator at Broad Institute. 60+ peer-reviewed publications.
Board-certified hematologist-oncologist. Led 15+ Phase I/II trials. MD from Harvard Medical School.
CRISPR technology expert. Former senior scientist at Editas Medicine. PhD in Genetics, MIT.
Our advisory board includes Nobel laureates, former FDA officials, and industry pioneers.
MIT Institute Professor — Biomaterials & Drug Delivery
Children's Hospital Boston — Stem Cell Biology
Former NIH Director — Genomics & Public Health
Nobel Laureate — CRISPR Gene Editing
Our work is published in the world's leading scientific journals.
Chen J, Vasquez E, et al. — Nature Medicine, 2024
Patel R, Okafor A, et al. — The Lancet, 2024
Liu W, Chen J, et al. — Nature Biotechnology, 2023
Collaborating with academic medical centers, research institutes, and industry partners globally.
Whether you're a researcher, investor, or healthcare professional — we'd love to connect.